Signal
44 articles covering "clinical-trials"
Phase 3 data presented at AAN 2026 show azetukalner nearly halved seizure frequency in treatment-resistant focal epilepsy, with 38% of long-term patients achieving over a year of seizure freedom.
Phase 3 RASolute 302 data show the oral RAS inhibitor extending median overall survival to 13.2 months versus 6.7 months on chemotherapy, sending Revolution Medicines shares up nearly 40 percent.
Two companion trials published in Nature Medicine show oral FMT capsules raised immunotherapy response rates to 80% in lung cancer and 75% in melanoma, while reducing toxic side effects in kidney cancer.
Phase 3 PreVenTB trial of 12,717 people across India shows VPM1002 cuts extrapulmonary tuberculosis by 50%, but neither candidate prevents pulmonary TB or latent infection.
United Therapeutics' miroliverELAP, an external bioengineered liver built on a decellularized pig scaffold seeded with human cells, receives FDA RMAT designation after all five Phase 1 patients survived treatment.
The Boston biotech closes a Series D round to advance ER-100, the first FDA-cleared therapy that uses partial epigenetic reprogramming to reverse cellular aging in humans.
Two bipartisan Senate bills would create a VA Office of Novel Therapeutics and fund psychedelic research centers, while states enact their own laws and Phase 3 trials advance.
Full results from Novo Nordisk's EVOKE and EVOKE+ trials, published in The Lancet, show oral semaglutide had no effect on cognitive decline over two years despite reducing key cerebrospinal fluid markers of neuroinflammation and tau pathology by roughly 10 percent.
The SWOG S2419 BioFront study is the first large-scale randomized trial testing whether a daily oral bacterial supplement can boost immunotherapy outcomes in advanced kidney cancer.
The TWIN-VT trial used personalized computational heart models to guide ventricular tachycardia ablation, with all 10 patients remaining arrhythmia-free after more than a year.
Neuralink's VOICE trial decoded silent neural signals from an ALS patient's brain into synthesized speech as the company's BCI program scales to 21 participants worldwide.
Texas will fully fund a $50 million ibogaine trial through 11 universities after no drug company met partnership terms, targeting PTSD, addiction, and TBI in veterans.